Journal
FEBS LETTERS
Volume 587, Issue 9, Pages 1271-1274Publisher
WILEY
DOI: 10.1016/j.febslet.2013.02.027
Keywords
PCSK9; Reverse cholesterol transport; Low-density lipoprotein receptor; Atherosclerosis
Funding
- National Nature Scientific Funding of China [81170190]
Ask authors/readers for more resources
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of low-density lipoprotein receptor (LDLRs) molecules expressed on the cell surface. Gene inactivation of PCSK9 reduces the areas of atherosclerotic lesions in mice, and the effect is mainly dependent on LDLRs. Furthermore, a positive relationship between PCSK9 and cholesterol accumulation in the wall of the aorta has been established. However, the mechanism remains unknown. As PCSK9 is mainly expressed in atherosclerotic plaque and in the liver, we hypothesize that PCSK9 might increase oxidized LDL uptake and impair macrophage-mediated reverse cholesterol transport, contributing to the development of atherosclerosis. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available